67 results
8-K
EX-10.1
KPRX
Kiora Pharmaceuticals Inc
6 Jan 21
EyeGate Enters Into Agreement for $8.0 Million Private Placement
6:55am
).
“Proceeding” means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial proceeding … or investigation pending or, to the knowledge of the Company, threatened against or affecting the Company, any Subsidiary or any of their respective
8-K
EX-10.1
KPRX
Kiora Pharmaceuticals Inc
30 Sep 19
EyeGate Enters Into Agreement for $1.9 Million Private Placement
6:55am
).
“Proceeding” means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial … , inquiry, notice of violation, proceeding or investigation pending or, to the knowledge of the Company, threatened against or affecting the Company
8-K
EX-10.1
KPRX
Kiora Pharmaceuticals Inc
15 Jun 23
Kiora Pharmaceuticals and Sentrx Animal Care Amend Existing Manufacturing Licensing Agreement for KIO-201
4:59pm
of any of its covenants or other obligations hereunder; (ii) any claim, demand, suit, proceeding, investigation, or other action of any nature related … to any Licensor intellectual property; or (iii) any claim, demand, suit, proceeding, investigation, or other action of any nature relating
8-K
EX-10.1
KPRX
Kiora Pharmaceuticals Inc
31 Dec 19
EyeGate Announces $5.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
4:05pm
).
“Placement Agent” means H.C. Wainwright & Co., LLC.
“Proceeding” means an action, claim, suit, investigation or proceeding (including, without … limitation, an informal investigation or partial proceeding, such as a deposition), whether commenced or threatened.
“Prospectus” means the final base
8-K
EX-10.2
KPRX
Kiora Pharmaceuticals Inc
15 Jun 23
Kiora Pharmaceuticals and Sentrx Animal Care Amend Existing Manufacturing Licensing Agreement for KIO-201
4:59pm
Licensee's breach of any representation, warranty, covenant, or obligation under this Agreement, (b) any claim, demand, suit, proceeding, investigation … , or (c) any claim, demand, suit, proceeding, investigation, or other action of any nature relating to or arising out of Licensee's action or inaction
8-K
EX-10.1
stdrjg4 htizty
2 Oct 18
EyeGate Pharmaceuticals Signs Technology Transfer and License Agreement with SentrX Animal Care
6:58am
8-K
EX-10.1
4ydfv0o966tl5lj
10 Aug 21
EyeGate Announces $10.75 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
6:55am
8-K
EX-10.1
j1bpc
13 Apr 18
EyeGate Announces $11.25 Million Public Offering
12:00am
8-K
EX-10.1
4ue 0ja9a6
1 Feb 24
Kiora Pharmaceuticals Announces Private Placement of up to Approximately $45 Million
7:01am
8-K
EX-10.2
xkgqsbhzjpuw1ima4
31 Dec 19
EyeGate Announces $5.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
4:05pm
8-K
EX-1.1
n405y
6 Jun 23
Kiora Pharmaceuticals Announces Pricing of $5.5 Million Underwritten Public Offering
4:52pm
8-K
EX-10.2
w2wwj
10 Aug 21
EyeGate Announces $10.75 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
6:55am
8-K
EX-10.1
2g1fdnkro4s7 t23gm
31 Jan 24
Entry into a Material Definitive Agreement
5:14pm
8-K
EX-2.1
7s00jlyoin47kva
21 Dec 20
EyeGate Pharma Announces Transformative Acquisition of Panoptes Pharma
6:55am
8-K
EX-1.1
xechhhhzdsucled6ks
26 Jul 22
Kiora Pharmaceuticals Announces Pricing of $5.2 Million Underwritten Public Offering
4:31pm